About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06605443

Precision Medicine for L/GCMN and Melanoma 2

The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for t...

Lead sponsor: Fundacion Clinic per a la Recerca Biomédica•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Susana Puig Sardà, PhD, MD

CONTACT

+34932275400 spuig@clinic.cat

Adrián López Canosa, PhD

CONTACT

lopez64@recerca.clinic.cat

Sponsors

Lead Sponsor

Fundacion Clinic per a la Recerca Biomédica

Collaborators

Hospital Clinic of Barcelona

This is a unicentric national prospective observational study aimed at evaluating the use of two devices (skin patch and breath analyzer) for the non or minimally invasive diagnosis of metastatic melanoma with a total duration of 24 months. The study will be based on the obtention of different patterns of volatile organic compounds using the aforementioned devices for melanoma patients with and without metastasis. The results will be compared with the standard procedures for the detection of metastatic melanoma (standard imaging techniques such as PET, MRI, etc.) and correlated with standard prognostic biomarkers (cfDNA mutations in BRAF, NRAS, etc.) obtained using liquid biopsy.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Be over 18 years old
•Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)

Exclusion Criteria

•Not signing the informed consent form
•Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles

Related studies

RECRUITINGPhase 1/2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917 · Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer

RECRUITINGPhase 1/2

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT07410676 · Cancer, Sarcoma, and more

RECRUITINGPhase 1

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

NCT06545682 · Melanoma (Skin Cancer), Breast Cancer, and more

Enrolling By Invitation

Impact and Lived Experience of Parents of a Child With a Large or Giant Congenital Melanocytic Nevus

NCT06934759 · Congenital Melanocytic Nevi, Congenital Melanocytic Nevus, and more

Not Yet RecruitingPhase 3

Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II

NCT07552597 · Melanoma (Skin Cancer)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 27, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment100

Start dateJan 2025

Last updatedFeb 27, 2025

Condition

Melanoma (Skin Cancer)Nevi and Melanomas Congenital Melanocytic Nevus

Locations shown

Hospital Clínic de Barcelona (Dermatology service)

Barcelona

Hospital Clínic Barcelona

Barcelona

Hospital Clínic Barcelona

Barcelona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions